President’s Letter | November 2020
From the Desk of Samantha Guild It’s hard to believe that we’re nearing the holiday season and the end of…
Blog - Melanoma360
11/12/2020
President’s Letter | November 2020
From the Desk of Samantha Guild It’s hard to believe that we’re nearing the holiday season and the end of…
|
11/12/2020
Survivor Spotlight: Stephanie Bowen, Stage IV Survivor
A Woman of Determination By Mara Klecker The second diagnosis came just days before Christmas 2010, almost exactly a decade…
|
11/12/2020
Survivor Spotlight: Tom Lauritzen, Stage III Survivor
On the Road Again…Soon By, Alicia Rowell Tom Lauritzen has lived his whole life in Pittsburgh, Pennsylvania, save for a…
|
11/12/2020
In Plain English—Neo-Adjuvant Therapy for Palpable/Resectable Stage III Melanoma
By Kim Margolin, M.D. In this chapter of “In Plain English,” we will describe the concept of neo-adjuvant therapy. Certain terms…
|
09/29/2020
Have You Checked Out Our New Website?
AIM announced the launch of our redesigned website last week. Have you had an opportunity to take a look? Every…
09/29/2020
President’s Letter |September 2020
From the Desk of Samantha Guild The fall is upon us, and here at AIM at Melanoma, we’re busy with…
|
09/29/2020
Joe Small: Stage III Survivor Spotlight
By, Alicia Rowell It was 2016—October, specifically—when Joe Small showed a little spot on his right forearm to his doctor…
|
09/29/2020
In Plain English: What is a “Triplet,” and Why Does it Matter in Melanoma?
By Kim Margolin, M.D. A “triplet” is the casual term to describe the combination of three drugs to treat cancer.…
|
06/03/2020
President’s Update June | 2020
June|2020 Greetings to the AIM at Melanoma community, Thank you for so many thoughtful acknowledgments and heartfelt tributes for my…
|
06/03/2020
AIM’s Steps Against Melanoma Walks Go Virtual
AIM’s Steps Against Melanoma walks have been a symbol of hope and support for our community for many years.…
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026